Bridging the gap: Facilities and technologies for development of early stage therapeutic mAb candidates

mAbs

Volumn 3, Issue 5, 2011, Pages 440-452

  Munro, Trent P ^a   Mahler, Stephen M ^a   Huang, Edwin P ^a   Chin, David Y ^a   Gray, Peter P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Biologics; Cell culture; CHO cells; Monoclonal antibody; Preclinical development

Indexed keywords

ADALIMUMAB; ARIPIPRAZOLE; ATORVASTATIN; BEVACIZUMAB; CLOPIDOGREL; ENOXAPARIN; ESOMEPRAZOLE; ETANERCEPT; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLATIRAMER; INFLIXIMAB; INSULIN GLARGINE; MONOCLONAL ANTIBODY; MONTELUKAST; OLANZAPINE; PIOGLITAZONE; QUETIAPINE; RITUXIMAB; ROSUVASTATIN; TRASTUZUMAB; VALSARTAN;

CELL LINE; DRUG QUALITY; HUMAN; MAMMAL CELL; NONHUMAN; PRODUCT DEVELOPMENT; REVIEW;

ACADEMIC MEDICAL CENTERS; ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CRICETINAE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; MICE; RESEARCH DESIGN; TECHNOLOGY, PHARMACEUTICAL;

EID: 80052590056     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.5.16968     Document Type: Review

References (66)

1. Intelligence LMB. Top 30 Biologics 2010. R&D Pipeline News 2011.
2. Maggon K. Twenty Best Selling Drugs 2010. Knol Publishing 2011. http://knol.google.com/k/krishan- maggon/top-ten-twenty-best-selling-drugs- 2010/3fy5eowy8suq3/141
3. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs 2009; 1:443-52.
4. Petering J, McManamny P, Honeyman J. Antibody therapeutics - the evolving patent landscape biotechnology annual review 2011. N Biotechnol 2011; In press.
5. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008; 8:473-80.
6. Aggarwal S. What's fueling the biotech engine-2009-2010. Nat Biotechnol 2010; 28:1165-71.
7. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 2010; 28:917-24.
8. Reichert JM. Metrics for antibody therapeutics development. MAbs 2010; 2:695-700.
9. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7.
10. Tjandra JJ, Ramadi L, Mckenzie IFC. Development of Human Antimurine Antibody (Hama) Response in Patients. Immunol Cell Biol 1990; 68:367-76.
11. Winter G, Milstein C. Man-made antibodies. Nature 1991; 349:293-9.
12. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen- binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81:6851-5.
13. Jones ST, Bendig MM. Rapid PCR-cloning of fulllength mouse immunoglobulin variable regions. Biotechnology (NY) 1991; 9:88-9.
14. Getts DR, Getts MT, McCarthy DP, Chastain EML, Miller SD. Have we overestimated the benefit of human(ized) antibodies? MAbs 2010; 2:682-94.
15. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348:552-4.
16. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222:581-97.
17. Bradbury AR, Sidhu S, Dubel S, McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 2011; 29:245-54.
18. Jones ML, Seldon T, Smede M, Linville A, Chin DY, Barnard R, et al. A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. J Immunol Methods 2010; 354:85-90.
19. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006; 1:755.
20. Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JM, Yeung YA, et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 2003; 21:163-70.
21. Kellermann SA, Green LL. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotech 2002; 13:593-7.
22. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008; 20:450-9.
23. Jakobovits A, Amad RG, Yang X, RoskoS L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007; 25:1134-43.
24. Bradley A. Kymouse Platform to generate highly selective, potent and well-tolerated human antibody-based biopharmaceuticals. PEGS Summit, Boston 2011.
25. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. mAbs 2011; 3:243-52.
26. Loo L, Robinson MK, Adams GP. Antibody engineering principles and applications. Cancer J 2008; 14: 149-53.
27. Presta L. Antibody engineering for therapeutics. Curr Opin Struct Biol 2003; 13:519-25.
28. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22:1393-8.
29. Rita Costa A, Elisa Rodrigues M, Henriques M, Azeredo J, Oliveira R. Guidelines to cell engineering for monoclonal antibody production. Eur J Pharm Biopharm 2010; 74:127-38.
30. Potgieter TI, Cukan M, Drummond JE, Houston-Cummings NR, Jiang Y, Li F, et al. Production of monoclonal antibodies by glycoengineered Pichia pastoris. J Biotechnol 2009; 139:318-25.
31. Hou JJC, Codamo J, Pilbrough W, Hughes B, Gray PP, Munro TP. New frontiers in cell line development: Challenges for biosimilars. J Chem Technol Biotechnol 2011; 86:895-904.
32. Codamo J, Munro TP, Hughes BS, Song M, Gray PP. Enhanced CHO Cell-Based Transient Gene Expression with the Epi-CHO Expression System. Mol Biotechnol 2011; 48:109-15.
33. Backliwal G, Hildinger M, Hasija V, Wurm FM. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol Bioeng 2008; 99:721-7.
34. Wulhfard S, Tissot S, Bouchet S, Cevey J, De Jesus M, Hacker DL, et al. Mild hypothermia improves transient gene expression yields several fold in Chinese hamster ovary cells. Biotechnol Prog 2008; 24:458-65.
35. Rajendra Y, Kiseljak D, Baldi L, Hacker DL, Wurm FM. A simple high-yielding process for transient gene expression in CHO cells. J Biotechnol 2011; 153:22-6.
36. Codamo J, Hou JJC, Hughes BS, Gray PP, Munro TP. Efficient mAb production in CHO cells incorporating PEI-mediated transfection, mild hypothermia and the co-expression of XBP-1. J Chem Technol Biotechnol 2011; 86:923-34.
37. Schimke RT. Gene amplification in cultured animal cells. Cell 1984; 37:705-13.
38. de la Cruz Edmonds MC, Tellers M, Chan C, Salmon P, Robinson DK, Markusen J. Development of transfection and high-producer screening protocols for the CHOK1SV cell system. Mol Biotechnol 2006; 34:179-90.
39. Antoniou M, Harland L, Mustoe T, Williams S, Holdstock J, Yague E, et al. Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 2003; 82:269-79.
40. Zahn-Zabal M, Kobr M, Girod PA, Imhof M, Chatellard P, de Jesus M, et al. Development of stable cell lines for production or regulated expression using matrix attachment regions. J Biotechnol 2001; 87:29-42.
41. Browne SM, Al-Rubeai M. Selection methods for high-producing mammalian cell lines. Trends Biotechnol 2007; 25:425-32.
42. Pilbrough W, Munro TP, Gray P. Intraclonal protein expression heterogeneity in recombinant CHO cells. PLoS One 2009; 4:8432.
43. Sleiman RJ, Gray PP, McCall MN, Codamo J, Sunstrom NA. Accelerated cell line development using two-color fluorescence activated cell sorting to select highly expressing antibody-producing clones. Biotechnol Bioeng 2008; 99:578-87.
44. Song M, Raphaelli K, Jones ML, Aliabadi-Zadeh K, Leung KM, Crowley D, et al. Clonal selection of high producing, stably transfected HEK293 cell lines utilizing modified, high-throughput FACS screening. J Chem Technol Biotechnol 2011; 86:935-41.
45. Dietmair S, Nielsen LK, Timmins NE. Engineering a mammalian super producer. J Chem Technol Biotechnol 2011; 86:905-14.
46. Liu PQ, Chan EM, Cost GJ, Zhang L, Wang J, Miller JC, et al. Generation of a triple-gene knockout mammalian cell line using engineered zinc-finger nucleases. Biotechnol Bioeng 2010; 106:97-105.
47. Muller N, Derouazi M, Van Tilborgh F, Wulhfard S, Hacker DL, Jordan M, et al. Scalable transient gene expression in Chinese hamster ovary cells in instrumented and non-instrumented cultivation systems. Biotechnol Lett 2007; 29:703-11.
48. Liu HF, Ma J, Winter C, Bayer R. Recovery and purification process development for monoclonal antibody production. mAbs 2010; 2:480-99.
49. Gagnon P. Monoclonal antibody purification with hydroxyapatite. N Biotechnol 2009; 25:287-93.
50. Chamberlain P. Preclinical strategies and safety issues in developing therapeutic monoclonal antibodies. N Biotechnol 2011; In press.
51. Snodin DJ, Ryle PR. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals. BioDrugs 2006; 20:25-52.
52. Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, et al. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. mAbs 2009; 1:505-16.
53. Lynch CM, Grewal IS. Preclinical safety evaluation of monoclonal antibodies. Handb Exp Pharmacol 2008; 19-44.
54. Lynch CM, Hart BW, Grewal IS. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. mAbs 2009; 1:2-11.
55. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008; 97:2426-47.
56. Petsch D, Anspach FB. Endotoxin removal from protein solutions. J Biotechnol 2000; 76:97-119.
57. Zoon K. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. In: FDA, Ed 1997.
58. th meeting, October 1996. Wkly Epidemiol Rec 1997; 141-5.
59. Rathore AS. Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 2009; 27:546-53.
60. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36.
61. Skerra A, Gebauer M. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009; 13:245-55.
62. Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaia N. The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329-39.
63. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767-74.
64. Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther 2010; 10:1011-8.
65. Cloonan N, Waddell N, Grimmond SM. The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics. IDrugs 2010; 13:778-81.
66. Flatman S, Alam I, Gerard J, Mussa N. Process analytics for purification of monoclonal antibodies. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848:79-87.